Thoraflex Hybrid
Vascutek, Ltd. · Decision date Oct 16, 2025
What did the FDA decide?
FDA records P210006/S014 as a supplement to PMA P210006, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 16, 2025.
FDA approval order statement
changes to the graft manufacturing process with regard to particulate removal and inspections
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P210006/S014
- Regulatory pathway
- PMA supplement
- Applicant
- Vascutek, Ltd.
- Product code
- QSK
- Decision code
- OK30
- Decision date
- Oct 16, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Hybrid stent graft, thoracic aortic lesion treatment.
- Applicant
- Vascutek, Ltd.
- Product code
- QSK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210006. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210006 · Original PMA
Thoraflex Hybrid
P210006/S013 · Related supplement
Thoraflex Hybrid
P210006/S014 received
Application receipt date recorded by FDA.
P210006/S014 · FDA decision
30-Day Notice
P210006/S015 · Related supplement
Thoraflex Hybrid
P210006/S016 · Related supplement
Thoraflex Hybrid
P210006/S017 · Related supplement
Thoraflex Hybrid
P210006/S019 · Related supplement
Thoraflex Hybrid
P210006/S018 · Related supplement
Thoraflex Hybrid
Timeline entries are records held by MedtechLedger for P210006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Thoraflex HybridP210006 | Vascutek, Ltd. | PMA approval | Apr 19, 2022 | FDA |
Thoraflex HybridP210006/S013 | Vascutek, Ltd. | PMA supplement | Jul 30, 2025 | FDA |
Thoraflex HybridP210006/S015 | Vascutek, Ltd. | PMA supplement | Oct 29, 2025 | FDA |
Thoraflex HybridP210006/S016 | Vascutek, Ltd. | PMA supplement | Jan 29, 2026 | FDA |
Thoraflex HybridP210006/S017 | Vascutek, Ltd. | PMA supplement | Apr 20, 2026 | FDA |
Thoraflex HybridP210006/S019 | Vascutek, Ltd. | PMA supplement | Jun 24, 2026 | FDA |
Thoraflex HybridP210006/S018 | Vascutek, Ltd. | PMA supplement | Sep 8, 2026 | FDA |
Explore the linked device profile
Other records with product code QSK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AMDS Hybrid ProsthesisP250055 | Artivion, Inc | PMA approval | Jun 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vascutek, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Newmains Ave., Inchinnan, PA49RR
Sources and methodology
- Original FDA record: P210006/S014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




